Pharmact Holding AG is the think tank for medical products and provides a platform for its subsidiaries.
The company owns various patents and other intellectual property rights. These rights are provided to its subsidiaries, which are organized in the fields of research & development, production, distribution and organization.
Starting in May 2020 the international distribution is coordinated out of Mannheim. Our affiliate in the United States of America, Pharmact Healthcare Inc. is located in Chapel Hill, North Carolina. Both locations will intensive support the studies for the approval of the patented active ingredient.
Pharmact is a biopharmaceutical company which has used its broad expertise in the treatment of arteriosclerosis to successfully complete the development of a new therapeutic drug for a number of diseases. Several immunoassay rapid tests have been developed in parallel. These point-of-care tests are intended for use in early diagnostics, for example in the screening of a developing diabetes melitus.
The company has developed the new molecule by using a genetic engineered technology process. Meanwhile, patent applications for the substance and a number of different treatments have been filed worldwide. The novel substance provides us with the platform for the approval process we have initiated in Europe, the USA and possibly other sites in the same time.
The pharmaceutical substance is GMP conform and is available in several lots. Until the end of Q3. 2020 for animal testing, toxicology and safety. The clinical trial of the drug “BelACT” is scheduled to run in multiple locations around the world in parallel. We have started the required regulatory process and have prepared the entire study design for Phase I / II / IIA.
Since its foundation in 2014 in Berlin, the company was financed exclusively by the shareholders, stakeholder and private investments.
Our new medicine needs being conducted by clinical studies. Base are the good results out of animal trials. The next steps are prepared, this are the clinical trials for Phase I / II / IIa.
Further capital is required to carry out the planned studies. Therefore we will increase in equity. We have prepared the financial due diligence in getting the possibly in inviting third parties, for professional investors, for buying shares of our company.
For interest and for any further information, please do not hesitate to contact us by email “Investor”.